资讯

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug
Sarepta stock tanked Friday after a new patient death was uncovered, spurring an FDA request to halt shipments of an ...
Sarepta extends losses premarket after refusing FDA’s halt request
Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...
Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths
Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...
华尔街见闻 on MSN2 天
美国FDA：要求Sarepta Therapeutics暂停分销Elevidys，但被拒绝
美国食品药品管理局（FDA）要求Sarepta Therapeutics Inc.（SRPT）暂停分销Elevidys。 要求该公司暂停Elevidys临床试验。 研究的受试对象可能会面临不合理的风险。 该公司拒绝自愿停止发货Elevidys。
Sarepta slides as FDA places clinical hold on gene therapy clinical trials
Sarepta Therapeutics faces challenges as the FDA halts gene therapy trials for LGMD and revokes AAVrh74 platform designation.
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says
The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...
Sarepta Therapeutics股价因LGMD患者死亡事件面临FDA审查
Investing.com - 根据 InvestingPro 数据，年初至今股价已下跌超过88%的Sarepta Therapeutics (NASDAQ: SRPT )，在披露一名患者死亡事件后，面临新的监管挑战，FDA要求暂停其基因疗法Elevidys的发货。技术指标显示该股目前处于超卖区域。
FDA暂停Sarepta肌肉萎缩症基因疗法临床试验
Sarepta Therapeutics, Inc. (NASDAQ: SRPT )，目前市值为13.8亿美元，周一宣布美国食品药品监督管理局已对其用于肢带型肌肉萎缩症 (LGMD)的研究性基因疗法临床试验实施临床暂停。根据 InvestingPro ...
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...
Sarepta Refused FDA’s Request to Halt Elevidys Shipments
The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...